Michael Ehlers and Romesh Subramanian launch biotech with $50M, sea squirt-inspired RNA-editing tech

Lei Lei Wu

News Reporter

So, sea squirts.

More elegantly known as ascidians, these early vertebrates metamorphose from tadpoles into their tube-like, immobile adult forms. To do that, ascidians edit …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Michael Ehlers and Romesh Subramanian launch biotech with $50M, sea squirt-inspired RNA-editing tech

Lei Lei Wu

News Reporter

Sign up to read this article for free.

A rare neurological disease is Sage’s last, best hope after failures in depression

Novartis strikes radiopharma deal with Ratio worth up to $745M

Intellia touts first clinical outcomes on CRISPR-based ATTR amyloidosis asset

Scottish biotech debuts with ‘Trojan horse’ platform for cancer

Eisai terminates Phase 3 trial of Dravet drug, citing recruitment challenges

Are programs with compounded GLP-1s safe for your population?

Michael Ehlers and Ro­mesh Sub­ra­man­ian launch biotech with $50M, sea squirt-in­spired RNA-edit­ing tech

Lei Lei Wu

News Reporter

Sign up to read this article for free.

A rare neu­ro­log­i­cal dis­ease is Sage’s last, best hope af­ter fail­ures in de­pres­sion

No­var­tis strikes ra­dio­phar­ma deal with Ra­tio worth up to $745M

In­tel­lia touts first clin­i­cal out­comes on CRISPR-based AT­TR amy­loi­do­sis as­set

Scot­tish biotech de­buts with ‘Tro­jan horse’ plat­form for can­cer

Ei­sai ter­mi­nates Phase 3 tri­al of Dravet drug, cit­ing re­cruit­ment chal­lenges

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Michael Ehlers and Romesh Subramanian launch biotech with $50M, sea squirt-inspired RNA-editing tech

A rare neurological disease is Sage’s last, best hope after failures in depression

Novartis strikes radiopharma deal with Ratio worth up to $745M

Intellia touts first clinical outcomes on CRISPR-based ATTR amyloidosis asset

Scottish biotech debuts with ‘Trojan horse’ platform for cancer

Eisai terminates Phase 3 trial of Dravet drug, citing recruitment challenges

Are programs with compounded GLP-1s safe for your population?